This afternoon we watched Cerevel Therapeutics drop -5.5% to a price of $39.12 per share. The Mid-Cap Pharmaceutical company is now trading -9.85% below its average target price of $43.4. Analysts have set target prices ranging from $31.0 to $45.0 per share for Cerevel Therapeutics, and have given the stock an average rating of hold.
The stock has an above average percentage of its shares sold short at 8.2%, and a short ratio of 7.39. Since 15.32% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 85.3% of Cerevel Therapeutics's shares being owned by this investor type.
Institutions Invested in Cerevel Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Bain Capital Investors Llc | 36% | 65,679,781 | $2,569,721,431 |
| 2024-03-31 | Perceptive Advisors Llc | 6% | 10,794,876 | $422,349,523 |
| 2024-03-31 | Avoro Capital Advisors LLC | 4% | 7,555,555 | $295,611,089 |
| 2024-03-31 | Vanguard Group Inc | 4% | 7,463,911 | $292,025,517 |
| 2024-03-31 | Blackrock Inc. | 3% | 5,448,620 | $213,177,257 |
| 2024-03-31 | State Street Corporation | 2% | 3,528,470 | $138,051,388 |
| 2024-03-31 | FIL LTD | 2% | 3,249,000 | $127,117,125 |
| 2024-03-31 | Alpine Associates Management Inc. | 1% | 2,341,394 | $91,607,040 |
| 2024-03-31 | Paradigm Biocapital Advisors LP | 1% | 2,330,508 | $91,181,125 |
| 2024-03-31 | Pentwater Capital Management Lp | 1% | 2,220,000 | $86,857,500 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Cerevel Therapeutics.
